Novel Combo Shows Early Activity in PD-L1–Resistant NSCLC, Melanoma
Source: Cancer Network, November 2024
Glycan editing of cell surface glycans with E-602 may represent a novel therapeutic approach among patients with cancer.
Combining the first-in-class engineered human sialidase Fc fusion E-602 with cemiplimab (Libtayo) elicited early anti-tumor activity, proof-of-mechanism, and tolerability among patients with PD-L1–resistant solid tumors such as non–small cell lung cancer (NSCLC) and melanoma, according to findings from the phase 1/2 GLIMMER-01 trial (NCT05259696) presented at the 2024 Society for Immunotherapy of Cancer Annual Meeting (SITC).
Data showed that the E-602 combination produced tumor desialylation for 2 to 5 days following treatment despite rapidly clearing with a half-life of approximately 1 day. When excluding those with a baseline HYRDA histoscore of 20 or lower, tumor desialylation occurred in 9 of 10 patients.